Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program

Jan 09 2018

• By Sue Sutter

Pink Sheet Perspectives 2017 - 2018

Related Content

Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

Jun 10 2015

FDA's 21<sup>st</sup> Century Cures Plan Gives Patient-Focused Drug Development A Boost

Jul 10 2017

FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development

Sep 12 2017

FDA Ends Regularly Scheduled Patient-Focused Drug Development Meetings

Sep 29 2017

Patient Experience Data May Require Separate Label, Genentech Suggests

Sep 26 2017

Will Patient-Reported Data Require New Drug Labeling Framework?

May 06 2017

Patient-Focused Guidance Writing: FDA Aiming For 'Sweet Spot' In Advice

Dec 22 2017

Related Companies

Genentech, Inc.

Additional Topics

United States Clinical Trials Drug Review FDA Policy BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window